Latest revenue
$6.2M
as of 2026-03-31
Latest net income
$-25.1M
as of 2026-03-31
Net margin
-408.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $393.6M
- Enterprise value
- $393.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $3.95
- 52-wk low
- $1.21
- Beta
- —
- Shares out
- 110.6M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Our strategy is to develop degraders that modulate clinically validated disease pathways with best-in-class or first-in-class potential to address significant unmet patient needs. To date, our degraders…
AI summary unavailable — showing raw filing excerpt
Generated from CCCC's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all the other information in this Annual Report on Form 10-K, including the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. The risks and uncertainties described below and in our other filings with the SEC, may not be the only ones that we face. The occurrence of any of the events or developments described below, if they actually occur, could harm our…
AI summary unavailable — showing raw filing excerpt
Generated from CCCC's filing dated 2026-02-26
Profitability
Operating margin
-320.5%
4.6%Net margin
-292.1%
1.3%Return on equity
-40.9%
16.1%Return on assets
-29.2%
2.9%Leverage
Debt / equity
0.40×
35.4%Long-term debt / equity
0.00×
100.0%Debt / assets
28.5%
25.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $6.2M | -15.0% | $-25.1M | +4.5% | -408.5% |
Q4 2025 2025-12-31 | $11.0M | +112.8% | $-20.5M | +40.7% | -186.0% |
Q3 2025 2025-09-30 | $11.2M | -26.9% | $-32.2M | -30.4% | -286.4% |
Q2 2025 2025-06-30 | $6.5M | -46.2% | $-26.0M | -46.9% | -402.6% |
Q1 2025 2025-03-31 | $7.2M | +138.2% | $-26.3M | +7.2% | -363.7% |
Q4 2024 2024-12-31 | $5.2M | — | $-34.6M | — | -667.8% |
Q3 2024 2024-09-30 | $15.4M | +38.7% | $-24.7M | +8.8% | -160.6% |
Q2 2024 2024-06-30 | $12.0M | +350.7% | $-17.7M | +50.7% | -147.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on CCCC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$22.2K
Net activity
−$22.2K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CCCC
Institutional value
$66.1M
Total shares held
27.4M
Distinct holders
51
-50 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 7.0M | $18.4M | -99.2K (-1.4%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9M | $10.2M | — | New |
| 3 | WASATCH ADVISORS LP | 3.0M | $7.8M | -1.4M (-31.8%) | Trimmed |
| 4 | JPMORGAN CHASE & CO | 3.2M | $7.6M | +3.2M (+54114.5%) | Added |
| 5 | BlackRock, Inc. | 2.0M | $5.4M | +78.7K (+4.0%) | Added |
| 6 | JANE STREET GROUP, LLC | 1.2M | $3.3M | +372.1K (+42.5%) | Added |
| 7 | WELLS FARGO & COMPANY/MN | 867.9K | $2.3M | +58.7K (+7.2%) | Added |
| 8 | CONGRESS ASSET MANAGEMENT CO | 830.6K | $2.2M | — | New |
| 9 | VANGUARD FIDUCIARY TRUST CO | 484.1K | $1.3M | — | New |
| 10 | Walleye Capital LLC | 478.2K | $1.3M | +34.9K (+7.9%) | Added |
| 11 | DIMENSIONAL FUND ADVISORS LP | 442.5K | $1.2M | +146.0K (+49.3%) | Added |
| 12 | Connor, Clark & Lunn Investment Management Ltd. | 277.2K | $729.0K | +239.5K (+634.8%) | Added |
| 13 | LPL Financial LLC | 246.8K | $649.1K | +3.5K (+1.4%) | Added |
| 14 | Invesco Ltd. | 244.5K | $643.1K | -23.8K (-8.9%) | Trimmed |
| 15 | UBS Group AG | 215.9K | $567.8K | +163.1K (+309.2%) | Added |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 190.3K | $500.6K | +188.2K (+8708.3%) | Added |
| 17 | Hudson Bay Capital Management LP | 130.1K | $342.1K | +18.5K (+16.6%) | Added |
| 18 | Mariner, LLC | 127.5K | $334.2K | -533 (-0.4%) | Trimmed |
| 19 | AXQ CAPITAL, LP | 86.3K | $226.9K | — | New |
| 20 | Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group | 85.0K | $223.6K | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once CCCC's latest filing finishes processing.